Caribou Biosciences Inc
Caribou Biosciences Inc (CRBU) Options Open Interest
CRBU options open interest is — contracts. The 2-week average daily volume is 118 contracts across the chain.
Read more
Monitoring CRBU open interest helps you see where real money is positioned on Caribou Biosciences Inc's options and which strikes are attracting the most commitment from traders. Caribou Biosciences Inc's open interest reflects the total number of outstanding contracts that have not been closed or exercised, making it a powerful gauge of liquidity, conviction, and potential support and resistance zones. Use our scanner to monitor CRBU options open interest in real time and find the strikes that matter.
Open interest is distinct from volume: volume counts how many contracts are traded in a session, while open interest counts how many remain open at the end of the day. Rising CRBU options open interest alongside rising volume suggests new positions are being built, while falling open interest signals positions are being closed. Heavy open interest at specific strikes often acts as a magnet near expiration and can hint at where dealers and large traders expect Caribou Biosciences Inc to settle.
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors.
It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Pin risk into expiration, dealer positioning, liquidity checks for large orders — all of it starts with knowing where CRBU open interest is concentrated. Our scanner maps Caribou Biosciences Inc's open interest across every strike and expiry, flags unusual buildups, and lets you drill into the contracts that institutional money is actually holding. Trade Caribou Biosciences Inc's options open interest as the signal it is, not as an afterthought.
| 2.00 | — | 0.05 | 0.05 | 167% | +0.2004 | 1,712 |
| 2.50 | — | 0.05 | 0.05 | 215% | +0.1692 | 909 |
| 5.00 | — | 0.05 | 0.05 | 344% | +0.1256 | 812 |
| 1.00 | — | 0.70 | 0.70 | 511% | +0.7992 | 182 |
| 0.50 | 0.35 | 1.35 | 0.85 | 380% | +0.9301 | 150 |
| 2.00 | 0.05 | 0.80 | 0.43 | 22% | -1.0000 | 725 |
| 1.50 | 0.15 | 0.70 | 0.43 | 228% | -0.4908 | 146 |
| 0.50 | — | 0.05 | 0.05 | 359% | -0.0657 | 17 |
| 2.50 | 0.75 | 1.75 | 1.25 | 211% | -0.8392 | 10 |
| 1.00 | — | 0.65 | 0.65 | 818% | -0.1259 | 0 |
As of September 25, 2026
Follow the money
Track CRBU open interest across every strike and expiration, identify where conviction is building, and trade with the positioning data on your side.
Start your 14-day free trial→